SEC Form 4 · accession 0001193125-26-356847
Humacyte, Inc. · HUMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith Anthony Jones
Director
Period of report
Aug 17, 2026
Accepted (ET)
Aug 19, 2026 · 4:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001818382
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 17, 2026 | P | 30,000 | $0.594 | A | 30,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.590 to $0.596. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.